MapLight Therapeutics enters $100 million at-the-market share sale agreement with Leerink Partners
MPLT•MapLight Therapeutics entered an agreement on November 16, 2026, for an at-the-market offering of up to $100 million of voting common stock. Leerink Partners may receive commissions of up to 3% of gross sales, and MapLight is not obligated to sell shares.
1. Offering terms
MapLight Therapeutics entered a sales agreement with Leerink Partners on November 16, 2026, for an at-the-market offering of up to $100 million of voting common stock. Leerink will receive a commission of up to 3% of gross sales. MapLight has no obligation to sell shares and may suspend sales or terminate the agreement at any time.




